Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Lars Grimelius
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, L. Grimelius wrote the following 3 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. 2017

Ali, Abir Salwa / Grönberg, Malin / Federspiel, Birgitte / Scoazec, Jean-Yves / Hjortland, Geir Olav / Grønbæk, Henning / Ladekarl, Morten / Langer, Seppo W / Welin, Staffan / Vestermark, Lene Weber / Arola, Johanna / Österlund, Pia / Knigge, Ulrich / Sorbye, Halfdan / Grimelius, Lars / Janson, Eva Tiensuu. ·Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. · Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. · Department of Biopathology, Institut Gustave Roussy, Villejuif, France. · Department of Oncology, Oslo University, Oslo, Norway. · Department of Hepatology & Gastroenterology, Aarhus university Hospital, Aarhus, Denmark. · Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. · Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. · Department of Oncology, Odense University Hospital, Odense, Denmark. · Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. · Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki Finland. · Department of Oncology, Tampere University Hospital, Tampere, Finland. · Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark. · Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway. · Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. ·PLoS One · Pubmed #29112960.

ABSTRACT: BACKGROUND: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. MATERIALS AND METHODS: Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). RESULTS: All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. CONCLUSION: In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.

2 Article Expression of the coiled coil domain containing protein 116 in the pancreatic islets and endocrine pancreatic tumors. 2012

Tsolakis, Apostolos V / Grimelius, Lars / Islam, Md Shahidul. ·Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. apostolos.tsolakis@medsci.uu.se ·Islets · Pubmed #23072936.

ABSTRACT: AIMS: Coiled coil domain containing protein 116 (CCDC116) is a product of the gene coiled coil domain containing 116 located on human chromosome 22. Its function has not yet been established. The present study focuses on the expression of this protein in human pancreatic islets and in the endocrine pancreatic tumors (EPTs). METHODS AND RESULTS: Expression of the protein was evaluated by immunohistochemistry in endocrine pancreas from six patients and in various EPTs from 51 patients. In pancreatic islets, virtually all insulin, approx. 75% of the somatostatin, and approx. 60% of the pancreatic polypeptide (PP) cells were immunoreactive for the CCDC116 protein whereas glucagon, ghrelin and the exocrine cells were not. All insulinomas, gastrinomas, non-functioning sporadic tumors and the hereditary multihormonal EPTs were immunoreactive with variable relative incidence. Two of the three somatostatinomas, and one of the three ACTH-secreting tumors also expressed CCDC116. CONCLUSIONS: The CCDC116 protein is expressed in all islet cell types except the glucagon and ghrelin cells. Most of the EPTs also contained CCDC116 protein. These findings suggest that this protein may play some role for the above mentioned endocrine cells and tumors. Its function has to be investigated in future studies.

3 Article Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia. 2012

Kanakis, G / Kaltsas, G / Granberg, D / Grimelius, L / Papaioannou, D / Tsolakis, A V / Öberg, K. ·Department of Pathophysiology (Endocrine Unit), University of Athens Medical School, Mikras Asias 75, 11527, Athens, Greece. geokan@endo.gr ·J Clin Endocrinol Metab · Pubmed #22319031.

ABSTRACT: CONTEXT: Hypersecretion of PTHrP is a relatively common cause of malignancy-related hypercalcemia but has only been described in a few cases of neuroendocrine tumors (NET). OBJECTIVE: The aim of this case report is to describe the clinical syndrome, complex therapeutic interventions, and unusual complications caused by persistent PTHrP hypersecretion in a patient with a pancreatic NET. CASE ILLUSTRATION: A 58-yr-old male patient presented with nonspecific abdominal pain and was found to have severe hypercalcemia secondary to a well-differentiated NET of the pancreas associated with extensive liver metastases. Elevated ionized calcium levels accompanied by low serum PTH and remarkably elevated PTHrP concentrations were consistent with PTHrP-related hypercalcemia that proved to be resistant to various chemotherapeutic regimens and supportive therapy. Partial control of the humoral syndrome was obtained only after the application of cytoreductive interventions and the introduction of various molecular targeted therapies. Due to persistent PTHrP action, bone disease emerged in the form of brown tumors. DISCUSSION: The manifestation of paraneoplastic syndrome due to PTHrP hypersecretion, despite its rareness in NET, should be considered in the differential diagnosis of hypercalcemia in such tumors. Moreover, the appearance of bone lesions in this setting may be in the context of metabolic bone disease and could be misdiagnosed as bone metastases.